Zeposia

Chemical Nameozanimod
Dosage FormCapsules (oral; 0.23 mg, 0.46 mg, 0.92 mg)
Drug ClassModulators
SystemNervous
CompanyCelgene Corporation
Approval Year2020

Indication

  • Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Last updated on 12/8/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zeposia (ozanimod) Prescribing Information.2020Celgene Corporation, Summit, NJ